EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease

Summary

EpiSign and Geneyx announced a partnership to integrate DNA methylation episignature analysis with Geneyx's genomic and multi-omics platform for rare disease applications.